Hap Trading, LLC Uni Qure N.V. Put Options Transaction History

Hap Trading, LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2023 Aug 11, 2023	BUY	$11.12 - $22.2 $112,311 - $224,220	10,100 New	10,100 $115,000
Q4 2021 Feb 14, 2022	BUY	$20.24 - $36.01 $50,599 - $90,025	2,500 Added 5.46%	48,300 $1.37 Million
Q3 2021 Nov 10, 2021	SELL	$26.01 - $38.22 $10,404 - $15,288	-400 Reduced 0.87%	45,800 $920,000
Q2 2021 Aug 11, 2021	BUY	$29.97 - $37.17 $74,925 - $92,925	2,500 Added 5.72%	46,200 $1.04 Million
Q4 2020 Feb 16, 2021	SELL	$35.35 - $50.67 $12.3 Million - $17.7 Million	-348,800 Reduced 88.87%	43,700 $921,000
Q2 2020 Aug 10, 2020	SELL	$45.06 - $67.74 $54,072 - $81,288	-1,200 Reduced 0.3%	392,500 $1.52 Million
Q1 2020 May 08, 2020	BUY	$40.01 - $73.97 $13.7 Million - $25.4 Million	343,100 Added 678.06%	393,700 $2.99 Million
Q3 2019 Nov 12, 2019	SELL	$39.36 - $76.8 $783,264 - $1.53 Million	-19,900 Reduced 28.23%	50,600 $337,000
Q2 2019 Aug 14, 2019	BUY	$52.76 - $82.19 $3.72 Million - $5.79 Million	70,500 New	70,500 $59,000

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $270M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.